Skip to main content
CERS
NASDAQ Industrial Applications And Services

Cerus Q2 Revenue Beats, Raises 2026 Guidance on Strong IFC Demand

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.55
Mkt Cap
$579.066M
52W Low
$1.15
52W High
$3.47
52W Position info
122% above low
Off High info
27% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

CERS has more than doubled off its 52-week low of $1.15.

Summary

Cerus reported Q2 2026 product revenue of $57.4M (+10% YoY), raised full-year product revenue guidance to $229M–$231M, and boosted its IFC sales outlook to $23M–$25M, reflecting strong demand for its new fibrinogen complex.


Key Events · Earnings and Guidance · CERS

  • Q2 Revenue and Earnings Beat

    Product revenue of $57.4M grew 10% YoY, driven by IFC and platelet kit demand. Net loss narrowed to $2.9M ($0.01/share) from $5.7M ($0.03/share) a year ago.

  • 2026 Guidance Raised

    Full-year product revenue guidance raised at the low end to $229M–$231M (from $227M–$231M). IFC sales outlook boosted to $23M–$25M, up ~40–50% YoY, reflecting accelerating commercial adoption.

  • Non-GAAP Adjusted EBITDA Positive

    Adjusted EBITDA reached $3.0M in Q2, up from $0.9M a year ago, indicating improving operating leverage as revenue scales.

  • Balance Sheet and Debt Refinancing

    Cash and short-term investments stood at $56.3M at quarter-end. Completed a debt refinancing that reduced the term loan by $30M, partially funded by cash and a draw on a new lower-cost revolver.


Analysis · CERS · Industrial Applications And Services

A solid quarter for Cerus featured product revenue up 10% and a sharply narrower net loss. The real story, however, is the raised guidance — IFC sales are now expected to jump 40–50% this year, signaling that the new fibrinogen complex franchise is gaining real commercial traction. The balance sheet remains tight with $56.3M in cash against $65.1M in debt, but the debt refinancing and BARDA contract expansion provide some breathing room. This filing confirms the turnaround narrative is intact and the growth drivers are accelerating.

At the time of this filing, CERS was trading at $2.55 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $579.1M. The 52-week trading range was $1.15 to $3.47. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CERS - Latest Insights

CERS
Jul 30, 2026, 4:44 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.50
Real-time Price: $2.40 info
Change: -$0.100 (-4%) info
Market Cap: $579.066M info
CERS
Jun 08, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.60
Real-time Price: $2.40 info
Change: -$0.200 (-8%) info
Market Cap: $579.066M info
CERS
Jun 08, 2026, 8:42 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.71
Real-time Price: $2.40 info
Change: -$0.310 (-11%) info
Market Cap: $579.066M info
CERS
Jun 03, 2026, 4:17 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.66
Real-time Price: $2.40 info
Change: -$0.260 (-10%) info
Market Cap: $579.066M info
CERS
May 27, 2026, 12:52 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $2.82
Real-time Price: $2.40 info
Change: -$0.420 (-15%) info
Market Cap: $579.066M info